Jerusalem G., and Hustinx R. Nuclear Medicine. In: Canellos C.P., Lister T.A., and Young B. (Eds). The lymphomas (2006), Elsevier, Philadelphia 189-202
Isasi C.R., Moadel R.M., and Blaufow M.D. A meta-analysis of 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104 (2005) 1066-1074
Kabickova E., Sumerauer D., and Cumlivska E. Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease. Eur J Nucl Med Mol Imaging 33 (2006) 1025-1031
Moog F., Bangerter M., Kotzerke J., Guhlmann A., Frickhofen N., and Reske S.N. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 16 (1998) 603-609
Jerusalem G., Warland V., Najjar F., Paulus P., Fassotte M.F., Fillet G., et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Com 20 (1999) 13-20
Kostakoglu L., Leonard J.P., Kuji I., Coleman M., Vallabhajosula S., and Goldsmith S.J. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 94 (2002) 879-888
Kwee T.C., Kwee R.M., and Nievelstein R.A.J. Imaging in staging of malignant lymphoma: a systemic review. Blood 111 (2008) 504-516
Seam P., Juweid M.E., and Cheson D. The role of FDG-PET scans in patients with lymphoma. Blood 110 (2007) 3507-3516
La Fougère C., Pfluger T., Schneider V., Hacker M., Bröckel N., Morhard D., et al. Restaging of patients with lymphoma. Comparison of low dose CT (20 mAs) with contrast enhanced diagnostic CT in combined (18F)-FDG PET/CT. Nuklearmedizin 47 (2008) 37-42
Schaefer N.G., Hany T.F., Taverna C., Seifert B., Stumpe K.D., von Schulthess G.K., et al. Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging. Do we need contrast enhanced CT?. Radiology 232 (2004) 823-829
Raanani P., Shasha Y., and Perry C. Is CT still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?. Ann Oncol 17 (2006) 117-122
Rodriguez-Vigil B., Gomez-Leon N., Pinilla I., Hernández-Maraver D., Coya J., Martín-Curto L., et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 47 (2006) 1643-1648
Morimoto T., Tateishi U., Maeda T., Arai Y., Nakajima Y., and Edmund Kim E. Nodal status of malignant lymphoma in pelvic and retroperitoneal lymphatic pathways: comparison of integrated PET/CT with or without contrast enhancement. Eur J Radiol (2007) sous presse
Juweid M.E., Stroobants S., Hoekstra O.S., Mottaghy F.M., Dietlein M., Guermazi A., et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 25 (2007) 571-578
Zijlstra J.M., Lindauer-van der Werf G., Hoekstra O.S., Hooft L., Riphagen I.I., and Huijgens P.C. 18F-fluoro-deoxyglucose positron emission tomography for posttreatment evaluation of malignant lymphoma: a systemic review. Haematologica 91 (2006) 522-529
Terasawa T.N., Nishashi T., Hotta T., and Nagai H. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma. A systemic review. J Nucl Med 49 (2008) 13-21
Juweid M.E. 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?. J Nucl Med 49 (2008) 9-12
Facey K., Bradbury I., Laking G., and Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 11 (2007) 44
Bradbury I, Bonell E, Boynton J, Cummins E, Facey K, Iqbal K et al. Health Technology Assessment. Report 2: Positron emission tomography (PET) imaging in cancer management. Glasgow: Health Technology. Board for Scotland; 2002. No. 1903961319.
Haioun C., Itti E., Rahmouni A., Brice P., Rain J.D., Belhadj K., et al. (18F)-Fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106 (2005) 1376-1381
Hutchings M., Loft A., Hansen M., Pedersen L.M., Buhl T., Jurlander J., et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107 (2006) 52-59
Dann E.J., Bar-Shalom R., Tamir A., Haim N., Ben-Shachar M., Avivi I., et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 109 (2007) 905-909
Brepoels L., and Stroobants S. Is (18F)fluorodeoxyglucose positron emission tomography the ultimate tool for response and prognosis assessment?. Hematol Oncol Clin North Am 21 (2007) 855-869
MacManus M.P., Seymour J.F., and Hicks R.J. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging 7 (2007) 10-18
